β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells

Our previous data illustrated that activation of the canonical Wnt signaling pathway was enriched in triple-negative breast cancer and associated with reduced overall survival in all patients. To determine whether Wnt signaling may be a promising therapeutic target for triple-negative breast cancer, we investigated whether β-catenin was necessary for tumorigenic behaviors in vivo and in vitro. β-catenin expression level was significantly reduced in two human triple-negative breast cancer cell lines, MDA-MB-231 and HCC38, using lentiviral delivery of β-catenin-specific small hairpin RNAs (shRNAs). Upon implantation of the cells in the mammary fat pad of immunocompromised mice, we found that β-catenin shRNA HCC38 cells formed markedly smaller tumors than control cells and grew much more slowly. In in vitro assays, β-catenin silencing significantly reduced the percentage of Aldefluor-positive cells, a read-out of the stem-like cell population, as well as the expression of stem cell-related target genes including Bmi-1 and c-Myc. β-catenin-knockdown cells were also significantly impaired in their ability to migrate in wound-filling assays and form anchorage-independent colonies in soft agar. β-catenin-knockdown cells were more sensitive to chemotherapeutic agents doxorubicin and cisplatin. Collectively, these data suggest that β-catenin is required for triple-negative breast cancer development by controlling numerous tumor-associated properties, such as migration, stemness, anchorage-independent growth and chemosensitivity.

[1]  C. Liedtke,et al.  Genomic Profiling in Triple-Negative Breast Cancer , 2013, Breast Care.

[2]  N. Harbeck,et al.  Genomic Profiling in Luminal Breast Cancer , 2013, Breast Care.

[3]  E. Kuipers,et al.  β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer , 2013, Oncogene.

[4]  M. Dieci,et al.  Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies , 2013, Drugs.

[5]  C. Loddenkemper,et al.  WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer , 2013, EMBO molecular medicine.

[6]  K. Goss,et al.  APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphology , 2013, BMC Cancer.

[7]  H. Joensuu,et al.  Adjuvant treatments for triple-negative breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. von Minckwitz,et al.  Neoadjuvant treatments for triple-negative breast cancer (TNBC). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Weiss,et al.  Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity , 2012, Proceedings of the National Academy of Sciences.

[10]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[11]  Yonghe Li,et al.  The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer , 2012, Journal of cellular biochemistry.

[12]  K. Goss,et al.  Apc Mutation Enhances PyMT-Induced Mammary Tumorigenesis , 2011, PloS one.

[13]  H. Sinn,et al.  Triple-Negative Breast Cancer: Clinical and Histological Correlations , 2011, Breast Care.

[14]  J. Reis-Filho,et al.  β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.

[15]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[16]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[17]  K. Goss,et al.  A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer , 2010 .

[18]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[19]  W. Du,et al.  Specific killing of Rb mutant cancer cells by inactivating TSC2. , 2010, Cancer cell.

[20]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[21]  O. Olopade,et al.  CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors , 2010, Breast Cancer Research and Treatment.

[22]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. O'toole,et al.  Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Charles M Perou,et al.  A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. , 2009, Cancer research.

[25]  Edward J Oakeley,et al.  WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth , 2009, Breast Cancer Research.

[26]  Debra L Winkeljohn Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[27]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[28]  M. Leverkus Faculty Opinions recommendation of Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. , 2008 .

[29]  A. Fusco,et al.  Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.

[30]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[31]  S. Weiss,et al.  A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells , 2006, Nature Cell Biology.

[32]  B. Porse,et al.  Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block , 2006, Nature Immunology.

[33]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[34]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Karine Hovanes,et al.  β-catenin–sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer , 2001, Nature Genetics.

[36]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[37]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[38]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[39]  K. Goss,et al.  A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. , 2010, Current drug targets.

[40]  M. Hung,et al.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.